Stocks › CYTK

CYTOKINETICS INC

CYTK·Nasdaq·United States United States·USD
$50.78
-0.68 (-1.32%)
Close · Nov 20, 2026 · Close Prices from Tiingo.com
CYTK
CYTOKINETICS INC · Nasdaq
Nasdaq 100S&P 500
Filings
Default90D1Y5YALL
CYTKS&P 500 (rebased)
Congress BuyCongress SellInsider BuyInsider SellForm 1448-K ResultsLobbying
Loading price history…
Daily closes, adjusted for splits and dividends · Close Prices from Tiingo.comHover a marker, every one is a filing · move across the line for the crosshair

Congressional Trades

Recent trades of CYTK by members of U.S. Congress · 5 on record · 2 in the last 12 months
All congressional trades →
PoliticianStockTypeFiledTraded
Gilbert Ray Cisneros, Jr.Gilbert Ray Cisneros, Jr.House · D · CA CYTKCYTOKINETICS INC · Stock Purchase
$1,001 - $15,000
Oct 12, 2026 Sep 29, 2026 Filing ↗
Gilbert Ray Cisneros, Jr.Gilbert Ray Cisneros, Jr.House · D · CA CYTKCYTOKINETICS INC · Stock Purchase
$1,001 - $15,000
Jul 2, 2026 Jun 30, 2026 Filing ↗
Gilbert Ray Cisneros, Jr.Gilbert Ray Cisneros, Jr.House · D · CA CYTKCYTOKINETICS INC · Stock Purchase
$1,001 - $15,000
Nov 18, 2025 Oct 9, 2025 Filing ↗
Lisa C. McClainLisa C. McClainHouse · R · MI CYTKCYTOKINETICS INC · Stock Sale
$1,001 - $15,000
Aug 13, 2025 Jun 17, 2025 Filing ↗
Lisa C. McClainLisa C. McClainHouse · R · MI CYTKCYTOKINETICS INC · Stock Purchase
$1,001 - $15,000
Aug 13, 2025 Jun 11, 2025 Filing ↗

Whale Activity

Position changes in CYTK reported for 2026-09-30 by 535 institutional filers
Increased: 204New: 59Held: 64Decreased: 125Closed: 62No prior filing: 21
  • Increased204
  • New59
  • Held64
  • Decreased125
  • Closed62
  • No prior filing21
FilerSharesValueChange
BlackRock, Inc.21.0M$1.39Bincreased
T. Rowe Price Investment Management, Inc.18.9M$1.25Bincreased
WELLINGTON MANAGEMENT GROUP LLP10.6M$698.0Mincreased
STATE STREET CORP7.1M$470.8Mincreased
VANGUARD PORTFOLIO MANAGEMENT LLC6.8M$448.2Mincreased
VANGUARD CAPITAL MANAGEMENT LLC6.3M$413.0Mincreased
Avoro Capital Advisors LLC4.9M$323.0Mdecreased
BANK OF AMERICA CORP /DE/4.7M$312.1Mincreased
GEODE CAPITAL MANAGEMENT, LLC3.8M$248.4Mincreased
Polar Capital Holdings Plc9.6M$227.7Mincreased
Invesco Ltd.3.0M$198.8Mincreased
RTW INVESTMENTS, LP2.9M$188.6Mheld

Every 13F filer's complete reported book, every quarter since 2013-06-30. 13F itself excludes short positions, cash and most options.

Insider Trading

Net shares bought (+) or sold (−) on the open market by CYTK insiders, by quarter · Form 4
-250.0K-125.0K0125.0K250.0K2025 Q1: -186.3K2025 Q12025 Q2: -81.3K2025 Q22025 Q3: -57.6K2025 Q32025 Q4: -163.6K2025 Q42026 Q1: -147.4K2026 Q12026 Q2: -229.4K2026 Q22026 Q3: -215.0K2026 Q32026 Q4: -56.6K2026 Q4

Recent Insider Transactions

2,400 transactions on record · newest first
All insider activity →
InsiderTypeSharesPriceValueDate
Malik Fady IbrahamEVP Research & Development Sale −3,300 $51.73 $171K Nov 17, 2026 Form 4 ↗
Malik Fady IbrahamEVP Research & Development Sale −200 $52.59 $11K Nov 17, 2026 Form 4 ↗
Hessekiel JeffreyChief Legal & Admin Officer Sale −15.1K $52.62 $795K Nov 17, 2026 Form 4 ↗
Blum Robert IPresident & CEO · Director Sale −5,077 $53.22 $270K Nov 16, 2026 Form 4 ↗
Blum Robert IPresident & CEO · Director Sale −2,223 $54.08 $120K Nov 16, 2026 Form 4 ↗
Blum Robert IPresident & CEO · Director Sale −200 $55.21 $11K Nov 16, 2026 Form 4 ↗
PARSHALL B LYNNEDirector · Director Sale −2,555 $55.26 $141K Nov 9, 2026 Form 4 ↗
PARSHALL B LYNNEDirector · Director Sale −2,445 $54.17 $132K Nov 9, 2026 Form 4 ↗
Malik Fady IbrahamEVP Research & Development Sale −3,500 $62.93 $220K Nov 3, 2026 Form 4 ↗
Blum Robert IPresident & CEO · Director Sale −7,500 $62.81 $471K Nov 2, 2026 Form 4 ↗
Malik Fady IbrahamEVP Research & Development Sale −3,500 $64.01 $224K Oct 20, 2026 Form 4 ↗
Blum Robert IPresident & CEO · Director Sale −7,500 $62.88 $472K Oct 12, 2026 Form 4 ↗
Malik Fady IbrahamEVP Research & Development Sale −3,500 $61.38 $215K Oct 6, 2026 Form 4 ↗
Blum Robert IPresident & CEO · Director Sale −7,500 $65.46 $491K Sep 28, 2026 Form 4 ↗
Blum Robert IPresident & CEO · Director Option exercise +7,500 $10.60 $80K Sep 28, 2026 Form 4 ↗
Malik Fady IbrahamEVP Research & Development Sale −3,500 $68.29 $239K Sep 22, 2026 Form 4 ↗
Malik Fady IbrahamEVP Research & Development Option exercise +3,500 $7.80 $27K Sep 22, 2026 Form 4 ↗
Landry Robert EDirector Sale −1,000 $72.13 $72K Sep 15, 2026 Form 4 ↗
Blum Robert IPresident & CEO · Director Sale −97.9K $69.33 $6.8M Sep 15, 2026 Form 4 ↗
Blum Robert IPresident & CEO · Director Gift +97.9K $0.00 $0 Sep 14, 2026 Form 4 ↗

Fund Holders

Mutual funds and ETFs holding CYTK · SEC Form N-PORT
FundSharesValue% of fundAs of
T. Rowe Price Capital Appreciation Fund
T. ROWE PRICE CAPITAL APPRECIATION FUND, INC.
6.3M$535.5M0.76%Jun 30, 2026
iShares Core S&P Mid-Cap ETF
iShares Trust
4.6M$395.8M0.32%Jun 30, 2026
VANGUARD TOTAL STOCK MARKET INDEX FUND
VANGUARD INDEX FUNDS
4.3M$367.5M0.02%Jun 30, 2026
iShares Russell 2000 ETF
iShares Trust
3.4M$289.2M0.35%Jun 30, 2026
VANGUARD SMALL-CAP INDEX FUND
VANGUARD INDEX FUNDS
3.1M$265.3M0.14%Jun 30, 2026
VANGUARD HEALTH CARE FUND
VANGUARD SPECIALIZED FUNDS
3.3M$257.7M0.68%Jul 31, 2026
SMALLCAP World Fund Inc3.0M$255.3M0.27%Jun 30, 2026
Fidelity OTC Portfolio
Fidelity Securities Fund
2.3M$175.1M0.41%Jul 31, 2026
T. Rowe Price Mid-Cap Growth Fund, Inc.2.0M$168.0M0.73%Jun 30, 2026
VANGUARD SMALL-CAP GROWTH INDEX FUND
VANGUARD INDEX FUNDS
1.8M$152.8M0.32%Jun 30, 2026

Mutual funds and ETFs whose N-PORT filings list CYTK's shares (CUSIP 23282W605), each fund at its latest report since Apr 21, 2026, largest positions first. Bonds, options and short positions are left out.

Activist & Passive Stakes

Schedule 13D / 13G beneficial-ownership filings
  • Wellington Management Company LLPSCHEDULE 13G/A · passive (13G) · 10.7M shares7.3%
    Nov 16, 2026 · ↗
  • Wellington Investment Advisors Holdings LLPSCHEDULE 13G/A · passive (13G) · 10.7M shares7.7%
    Nov 16, 2026 · ↗
  • Wellington Group Holdings LLPSCHEDULE 13G/A · passive (13G) · 10.7M shares7.7%
    Nov 16, 2026 · ↗
  • Wellington Management Group LLPSCHEDULE 13G/A · passive (13G) · 10.7M shares7.7%
    Nov 16, 2026 · ↗
  • STATE STREET CORPORATIONSCHEDULE 13G · passive (13G) · 7.1M shares5.1%
    Nov 10, 2026 · ↗
  • Wellington Investment Advisors Holdings LLPSCHEDULE 13G/A · passive (13G) · 7.1M shares5.1%
    Aug 13, 2026 · ↗
  • Wellington Group Holdings LLPSCHEDULE 13G/A · passive (13G) · 7.1M shares5.1%
    Aug 13, 2026 · ↗
  • Wellington Management Group LLPSCHEDULE 13G/A · passive (13G) · 7.1M shares5.1%
    Aug 13, 2026 · ↗
  • Abigail P. JohnsonSCHEDULE 13G/A · passive (13G) · 5.2M shares3.9%
    Jul 8, 2026 · ↗
  • FMR LLCSCHEDULE 13G/A · passive (13G) · 5.2M shares3.9%
    Jul 8, 2026 · ↗

Corporate Lobbying

Estimated quarterly lobbying spending reported under the LDA, filings naming cytokinetics as client
$0$50K$100K$150K$200K2024 Q4: $10K20242025 Q1: $30K2025 Q2: $30K2025 Q3: $30K2025 Q4: $30K20252026 Q1: $30K2026 Q2: $30K2026 Q3: $30K2026
  • FARRAGUT PARTNERS LLPCYTOKINETICS INC. · 2026 Q3 · HCR$30K
    Filing ↗
  • FARRAGUT PARTNERS LLPCYTOKINETICS INC. · 2026 Q2 · HCR$30K
    Filing ↗
  • FARRAGUT PARTNERS LLPCYTOKINETICS INC. · 2026 Q1 · HCR$30K
    Filing ↗
  • FARRAGUT PARTNERS LLPCYTOKINETICS INC. · 2025 Q4 · HCR$30K
    Filing ↗
  • FARRAGUT PARTNERS LLPCYTOKINETICS INC. · 2025 Q3 · HCR$30K
    Filing ↗

Government Contracts

Federal awards to CYTOKINETICS INC · USAspending

No federal contract awards found for CYTOKINETICS INC.

U.S. Patents

Recent USPTO applications naming CYTOKINETICS INC

No USPTO patent applications found for CYTOKINETICS INC.

Annual Financials

From CYTK's 10-K filings · XBRL
Fiscal yearFY2025FY2024FY2023FY2022FY2021
Revenue$88.0M$18.5M$7.5M$94.6M$70.4M
Operating income-$612.3M-$536.2M-$496.2M-$324.2M-$186.3M
Net income-$785.0M-$589.5M-$526.2M-$389.0M-$215.3M
Diluted EPS-$6.54-$5.26-$5.45-$4.33-$2.80
Operating cash flow-$510.0M-$395.9M-$414.3M-$299.5M-$142.5M
Cash and equivalents$122.5M$94.9M$113.0M$65.6M$112.7M
Total assets$1.42B$1.40B$824.3M$1.01B$841.3M
Total liabilities$2.08B$1.54B$1.21B$1.12B$597.5M
Shareholders' equity-$659.6M-$135.4M-$386.3M-$107.9M$243.9M

As CYTOKINETICS INC tagged them in its 10-K filings: totals for the year on the income and cash-flow lines, values at the year's end on the balance-sheet lines. Latest 10-K, filed Feb 26, 2026 ↗

Stock Splits

Every split and reverse split in the price history
  • 1-for-6Reverse splitJun 25, 2013

Split dates and ratios from the price history · Close Prices from Tiingo.com

Material Events (8-K)

Corporate events filed with the SEC
  • 8-K · Items 2.02, 9.01Results of operationsNov 4, 2026
    EDGAR ↗
  • 8-K · Items 8.01, 9.01Other eventsAug 28, 2026
    EDGAR ↗
  • 8-K · Items 8.01Other eventsAug 13, 2026
    EDGAR ↗
  • 8-K · Items 2.02, 9.01Results of operationsAug 6, 2026
    EDGAR ↗
  • 8-K · Items 5.07Shareholder voteMay 27, 2026
    EDGAR ↗
  • 8-K · Items 8.01, 9.01Other eventsMay 8, 2026
    EDGAR ↗
  • 8-K · Items 8.01, 9.01Other eventsMay 5, 2026
    EDGAR ↗
  • 8-K · Items 2.02, 9.01Results of operationsMay 5, 2026
    EDGAR ↗

About CYTOKINETICS INC

From SEC EDGAR company records
Industry (SIC 2834)Pharmaceutical Preparations
SectorHealthcare
HeadquartersSOUTH SAN FRANCISCO, CA